Skip to main content

Table 2 Results of stereotactic radiosurgery (SRS) for brain metastases

From: Stereotactic radiosurgery (SRS) for brain metastases: a systematic review

Reference n(patients/lesions) Prescribed dose (median; range [Gy])* Median OS (m) 1-year PFS (%)
Pirzkall et al. 1998 [28] 236/311 20; 10-30 5.5 89
Cho et al. 1998 [81] 73/136 17.5; 6-50 7.8 80
Sneed et al. 1999 [27] 62/118a 18; 15-22 11.3 80
43/117b 17.5; 15-22 11.1 86
Varlotto et al. 2003 [82] 137/208 16; 12-25 Not given 90
Andrews et al. 2004 [18] 164/269c Not given; 15-24 6.5 82
Bhatnagar et al. 2006 [83] 205/4-18 lesions eachd 16; 12-20 8.0 71
  1. OS: overall survival in months; PFS: progression-free survival.
  2. *Prescription isodose or point varied, some series included SRS plus WBRT.
  3. aSRS only.
  4. bSRS plus WBRT (no significant difference in OS and PFS between both groups).
  5. cSRS plus WBRT.
  6. dSRS plus/minus WBRT.